GLP-1R receptor agonist polypeptide compound and its use

By designing a new structure of GLP-1R polypeptide compound, the problems of adverse reactions and low bioavailability of existing GLP-1R receptor agonists have been solved, and stronger glycemic and weight-reducing effects and longer half-life have been achieved. Safer and efficient treatment options.

CN118546214BActive Publication Date: 2024-12-03CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410928397.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-11
Publication Date
2024-12-03
Estimated Expiration
2044-07-11

AI Technical Summary

Technical Problem

Existing GLP-1R receptor agonists such as Semaglutide are limited due to adverse reactions such as nausea and vomiting, and are difficult to use for a long time, and have low bioavailability, which cannot meet the clinical needs of patients with type 2 diabetes.

Method used

Designed a new class of GLP-1R polypeptide compounds with a new structure, with an amino acid sequence of H-X1-EGTFTSDVSSYLEGQ-X2-X3-Bn-EFI-X4-X5-L-X6-RGRG, with a longer half-life and higher Bioavailability is prepared by polypeptide solid phase synthesis method to avoid adverse reactions and combined with pharmaceutically acceptable salts or carriers.

Benefits of technology

This peptide compound significantly activates the GLP-1 receptor, has stronger glycemic and weight-reducing effects, avoids adverse reactions such as nausea and vomiting, has a longer half-life and higher bioavailability, and is suitable for the treatment of type 2 diabetes. and the development of weight loss drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

The present invention discloses a GLP-1R receptor agonist polypeptide compound and its use, belonging to the field of polypeptide medicine. The amino acid sequence of the GLP-1R polypeptide compound is: H-X1-EGTFTSDVSSYLEGQ-X2-X3-B n ‑EFI‑X4‑X5‑L‑X6‑RGRG. The GLP‑1R polypeptide compound of the present invention has a more significant stimulatory effect on the receptor of human glucagon-like peptide‑1 (GLP‑1), and not only has the effects of lowering blood sugar and reducing weight, but also has a longer half-life and higher bioavailability, which can avoid the adverse reactions such as nausea and vomiting caused by long-term use of existing drugs, and can be used as an effective raw material for the preparation of drugs for treating or preventing diabetes or weight loss drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of polypeptide medicine, and in particular to a GLP-1R receptor agonist polypeptide compound and uses thereof. Background Art

[0002] The World Health Organization divides diabetes into type 1 diabetes, type 2 diabetes, gestational diabetes and special types of diabetes, among which type 2 diabetes accounts for the vast majority of diabetic patients. Type 2 diabetes is a serious metabolic disorder characterized by chronic hyperglycemia, and its causes are mainly related to lifestyle factors and genetic factors. The formation of type 2 diabetes is mainly related to insulin resistance and pancreatic β-cell defects. Insulin resistance is mainly manifested as the inability of insulin to play a normal role in target tissues, leading to metabolic disorders, while pancreatic β-cell defects are usually manifested as insufficient insulin secretion. Since type 2 diabetes may usually cause a variety of vascular and non-vascular complications including obesity, cardiovascular disease, renal failure, coronary artery disease, microvascular disease, retinopathy, etc., type 2 diabetes has posed a great threat to human health so far. Therefore, the development of safe and efficient hypoglycemic drugs is of great significance and value for controlling blood sugar in patients with type 2 diabetes.

[0003] At present, the main treatment drugs for diabetes include biguanides, sulfonylureas, α-glucosidase inhibitors, glinides, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and insulin. Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and is currently one of the most successful drugs for the treatment of diabetes. Compared with other types of hypoglycemic drugs, Semaglutide can not only lower blood sugar, but also provide weight loss effects. In addition, as a GLP-1 receptor agonist, Semaglutide also has the effect of regulating blood lipids, blood pressure and other hypoglycemic effects, which can reduce the risk of possible cardiovascular events while controlling blood sugar to provide better safety. Its target GLP-1 is a neuroendocrine hormone secreted by the small intestine. The hormone receptor is not only present in the regulatory area of ​​the brain, but also in the pancreas. At the same time, both regulatory areas can show control of blood sugar. Activating the GLP-1 receptor can promote insulin secretion and inhibit glucagon secretion in a glucose concentration-dependent manner, thereby increasing satiety, inhibiting food intake, delaying gastric emptying, etc., thereby achieving the ultimate goal of regulating blood sugar and losing weight.

[0004] Although Semaglutide is favored by patients with type 2 diabetes due to its good therapeutic effect, its dosage is still limited by adverse reactions such as nausea and vomiting. Therefore, it is urgent to develop new diabetes treatment drugs targeting GLP-1R to improve the effect of diabetes treatment and reduce the occurrence of adverse reactions, and provide new drug options and treatment plans for clinical application of patients with type 2 diabetes. Summary of the invention

[0005] Purpose of the invention: In view of the problems existing in the prior art, the present invention provides a class of GLP-1R polypeptide compounds with a novel structure or a pharmaceutically acceptable salt thereof; the GLP-1R polypeptide compounds of the present invention have an agonist effect on the receptor of human glucagon-like peptide-1 (GLP-1), and not only have the effects of lowering blood sugar and reducing weight, but also have a longer half-life and higher bioavailability, and can avoid the adverse reactions such as nausea and vomiting caused by long-term use of existing drugs.

[0006] The present invention also provides a pharmaceutical composition of the GLP-1R polypeptide compound and its use.

[0007] Technical solution: In order to achieve the above-mentioned purpose, the GLP-1R polypeptide compound of the present invention or its pharmaceutically acceptable salt, the amino acid sequence of the GLP-1R polypeptide compound is: H-X1-EGTFTSDVSSYLEGQ-X2-X3-B n -EFI-X4-X5-L-X6-RGRG;

[0008] wherein X1 is selected from an α-aminoisobutyric acid residue; X2 is selected from an α-aminoisobutyric acid residue, a 2-aminobutyric acid residue, a serine residue, an isovaline residue or an alanine residue; and X3 is selected from an α-aminoisobutyric acid residue or an alanine residue;

[0009] B n ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) on the side chain ε-amino n -CO2H modified lysine residue, wherein n is a natural number from 12 to 20, and its structural chemical formula is as follows:

[0010] Among them, B n is a known residue, see the literature: Discovery of the Once-Weekly Glucagon-LikePeptide-1 (GLP-1) Analogue Semaglutide, J. Med. Chem. 2015, 58, 7370-7380, wherein the size of n can be designed and prepared in different ways according to existing methods;

[0011] X4 is selected from an α-aminoisobutyric acid residue, a 2-aminobutyric acid residue, a norvaline residue, a valine residue, a serine residue or a 1-aminocyclobutanecarboxylic acid residue;

[0012] X5 is selected from the group consisting of tryptophan, 3-(1-naphthyl)-alanine residue, 3-(2-naphthyl)-alanine residue, tyrosine residue, phenylalanine residue, 4-chlorophenylalanine residue, 3-chlorophenylalanine residue or 3-trifluoromethylphenylalanine residue;

[0013] X6 is selected from a phenylalanine residue, a tyrosine residue, a leucine residue, an isoleucine residue, a valine residue or a 2-amino-3-methylhexanoic acid residue.

[0014] Optionally, n=12, 13, 14, 15, 16, 17, 18, 19, 20. More preferably, n is a natural number from 12 to 16, n is a natural number from 14 to 20, and n is a natural number from 16 to 20.

[0015] Preferably, the amino acid sequence of the GLP-1R polypeptide compound is selected from any one of the following:

[0016] SEQ ID NO:1

[0017] HZ-EGTFTSDVSSYLEGQ-ZAB 16 -EFI-AWLV-RGRG

[0018] SEQ ID NO:2

[0019] HZ-EGTFTSDVSSYLEGQ-Z1-AB 16 -EFI-AWLV-RGRG

[0020] SEQ ID NO:3

[0021] HZ-EGTFTSDVSSYLEGQ-SAB 16 -EFI-AWLV-RGRG

[0022] SEQ ID NO:4

[0023] HZ-EGTFTSDVSSYLEGQ-Z2-AB 16 -EFI-AWLV-RGRG

[0024] SEQ ID NO:5

[0025] HZ-EGTFTSDVSSYLEGQ-AZB 16-EFI-A-W-L-V-RGRG

[0026] SEQ ID NO:6

[0027] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z-W-L-V-RGRG

[0028] SEQ ID NO:7

[0029] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z1-W-L-V-RGRG

[0030] SEQ ID NO:8

[0031] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z3-W-L-V-RGRG

[0032] SEQ ID NO:9

[0033] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-V-W-L-V-RGRG

[0034] SEQ ID NO:10

[0035] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-S-W-L-V-RGRG

[0036] SEQ ID NO:11

[0037] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z4-W-L-V-RGRG

[0038] SEQ ID NO:12

[0039] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-A-Z5-L-V-RGRG

[0040] SEQ ID NO:13

[0041] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-A-Z6-L-V-RGRG

[0042] SEQ ID NO:14

[0043] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-A-Z7-L-V-RGRG

[0044] SEQ ID NO:15

[0045] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-A-Z8-L-V-RGRG

[0046] SEQ ID NO:16

[0047] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-A-Z9-L-V-RGRG

[0048] SEQ ID NO:17

[0049] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-A-F-L-V-RGRG

[0050] SEQ ID NO:18

[0051] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-A-W-L-F-RGRG

[0052] SEQ ID NO:19

[0053] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-A-W-L-Y-RGRG

[0054] SEQ ID NO:20

[0055] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-A-W-L-L-RGRG

[0056] SEQ ID NO:21

[0057] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-A-W-L-I-RGRG

[0058] SEQ ID NO:22

[0059] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-A-W-L-Z 10 -RGRG

[0060] SEQ ID NO:23

[0061] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-Z-W-L-V-RGRG

[0062] SEQ ID NO:24

[0063] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-Z1-W-L-V-RGRG

[0064] SEQ ID NO:25

[0065] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-Z3-W-L-V-RGRG

[0066] SEQ ID NO:26

[0067] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-V-W-L-V-RGRG

[0068] SEQ ID NO:27

[0069] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-S-W-L-V-RGRG

[0070] SEQ ID NO:28

[0071] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-Z4-W-L-V-RGRG

[0072] SEQ ID NO:29

[0073] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-A-Z5-L-V-RGRG

[0074] SEQ ID NO:30

[0075] H-Z-EGTFTSDVSSYLEGQ-Z-A-B16 -EFI-A-Z6-L-V-RGRG

[0076] SEQ ID NO:31

[0077] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-A-F-L-V-RGRG

[0078] SEQ ID NO:32

[0079] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-A-Z7-L-V-RGRG

[0080] SEQ ID NO:33

[0081] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-A-Z8-L-V-RGRG

[0082] SEQ ID NO:34

[0083] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-A-Z9-L-V-RGRG

[0084] SEQ ID NO:35

[0085] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-A-W-L-F-RGRG

[0086] SEQ ID NO:36

[0087] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-A-W-L-Y-RGRG

[0088] SEQ ID NO:37

[0089] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-A-W-L-L-RGRG

[0090] SEQ ID NO:38

[0091] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-A-W-L-I-RGRG

[0092] SEQ ID NO:39

[0093] H-Z-EGTFTSDVSSYLEGQ-Z-A-B 16 -EFI-A-W-L-Z 10 -RGRG

[0094] SEQ ID NO:40

[0095] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z1-Z5-L-V-RGRG

[0096] SEQ ID NO:41

[0097] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z1-Z6-L-V-RGRG

[0098] SEQ ID NO:42

[0099] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z1-F-L-V-RGRG

[0100] SEQ ID NO:43

[0101] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z1-Z7-L-V-RGRG

[0102] SEQ ID NO:44

[0103] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z1-Z8-L-V-RGRG

[0104] SEQ ID NO:45

[0105] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z1-Z9-L-V-RGRG

[0106] SEQ ID NO:46

[0107] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z1-W-L-F-RGRG

[0108] SEQ ID NO:47

[0109] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z1-W-L-Y-RGRG

[0110] SEQ ID NO:48

[0111] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z1-W-L-L-RGRG

[0112] SEQ ID NO:49

[0113] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z1-W-L-I-RGRG

[0114] SEQ ID NO:50

[0115] H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z1-W-L-Z 10 -RGRG

[0116] SEQ ID NO:51

[0117] H-Z-EGTFTSDVSSYLEGQ-A-A-B 15 -EFI-Z1-W-L-V-RGRG

[0118] SEQ ID NO:52

[0119] H-Z-EGTFTSDVSSYLEGQ-A-A-B 17 -EFI-Z1-W-L-V-RGRG

[0120] SEQ ID NO:53

[0121] H-Z-EGTFTSDVSSYLEGQ-A-A-B 18 -EFI-Z1-W-L-V-RGRG

[0122] SEQ ID NO:54

[0123] H-Z-EGTFTSDVSSYLEGQ-A-A-B 14 -EFI-Z1-W-L-V-RGRG

[0124] SEQ ID NO:55

[0125] H-Z-EGTFTSDVSSYLEGQ-A-A-B 19 -EFI-Z1-W-L-V-RGRG

[0126] SEQ ID NO:56

[0127] H-Z-EGTFTSDVSSYLEGQ-A-A-B 20 -EFI-Z1-W-L-V-RGRG

[0128] SEQ ID NO:57

[0129] H-Z-EGTFTSDVSSYLEGQ-A-A-B 13 -EFI-Z1-W-L-V-RGRG

[0130] SEQ ID NO:58

[0131] H-Z-EGTFTSDVSSYLEGQ-A-A-B 17 -EFI-Z3-W-L-V-RGRG

[0132] SEQ ID NO:59

[0133] H-Z-EGTFTSDVSSYLEGQ-A-A-B 18 -EFI-Z3-W-L-V-RGRG

[0134] SEQ ID NO:60

[0135] H-Z-EGTFTSDVSSYLEGQ-A-A-B 19 -EFI-Z3-W-L-V-RGRG

[0136] SEQ ID NO:61

[0137] H-Z-EGTFTSDVSSYLEGQ-A-A-B 15 -EFI-Z3-W-L-V-RGRG

[0138] SEQ ID NO:62

[0139] H-Z-EGTFTSDVSSYLEGQ-A-A-B 14 -EFI-Z3-W-L-V-RGRG

[0140] SEQ ID NO:63

[0141] H-Z-EGTFTSDVSSYLEGQ-A-A-B 13-EFI-Z3-W-L-V-RGRG

[0142] SEQ ID NO:64

[0143] H-Z-EGTFTSDVSSYLEGQ-A-A-B 13 -EFI-Z1-W-L-I-RGRG

[0144] SEQ ID NO:65

[0145] H-Z-EGTFTSDVSSYLEGQ-A-A-B 14 -EFI-Z1-W-L-I-RGRG

[0146] SEQ ID NO:66

[0147] H-Z-EGTFTSDVSSYLEGQ-A-A-B 15 -EFI-Z1-W-L-I-RGRG

[0148] SEQ ID NO:67

[0149] H-Z-EGTFTSDVSSYLEGQ-A-A-B 17 -EFI-Z1-W-L-I-RGRG

[0150] SEQ ID NO:68

[0151] H-Z-EGTFTSDVSSYLEGQ-A-A-B 18 -EFI-Z1-W-L-I-RGRG

[0152] SEQ ID NO:69

[0153] H-Z-EGTFTSDVSSYLEGQ-A-A-B 19 -EFI-Z1-W-L-I-RGRG

[0154] SEQ ID NO:70

[0155] H-Z-EGTFTSDVSSYLEGQ-A-A-B 12 -EFI-A-Z5-L-V-RGRG

[0156] SEQ ID NO:71

[0157] H-Z-EGTFTSDVSSYLEGQ-A-A-B 13 -EFI-A-Z5-L-V-RGRG

[0158] SEQ ID NO:72

[0159] H-Z-EGTFTSDVSSYLEGQ-A-A-B 14 -EFI-A-Z5-L-V-RGRG

[0160] SEQ ID NO:73

[0161] H-Z-EGTFTSDVSSYLEGQ-A-A-B 15 -EFI-A-Z5-L-V-RGRG

[0162] SEQ ID NO:74

[0163] H-Z-EGTFTSDVSSYLEGQ-A-A-B 17 -EFI-A-Z5-L-V-RGRG

[0164] SEQ ID NO:75

[0165] H-Z-EGTFTSDVSSYLEGQ-A-A-B 13 -EFI-A-Z6-L-V-RGRG

[0166] SEQ ID NO:76

[0167] H-Z-EGTFTSDVSSYLEGQ-A-A-B 14 -EFI-A-Z6-L-V-RGRG

[0168] SEQ ID NO:77

[0169] H-Z-EGTFTSDVSSYLEGQ-A-A-B 15 -EFI-A-Z6-L-V-RGRG

[0170] SEQ ID NO:78

[0171] H-Z-EGTFTSDVSSYLEGQ-A-A-B 17 -EFI-A-Z6-L-V-RGRG

[0172] SEQ ID NO:79

[0173] H-Z-EGTFTSDVSSYLEGQ-A-A-B 13 -EFI-A-Y-L-V-RGRG

[0174] SEQ ID NO:80

[0175] HZ-EGTFTSDVSSYLEGQ-AAB 14 -EFI-AYLV-RGRG

[0176] SEQ ID NO:81

[0177] HZ-EGTFTSDVSSYLEGQ-AAB 15 -EFI-AYLV-RGRG

[0178] SEQ ID NO:82

[0179] HZ-EGTFTSDVSSYLEGQ-AAB 16 -EFI-AYLV-RGRG

[0180] SEQ ID NO:83

[0181] HZ-EGTFTSDVSSYLEGQ-AAB 13 -EFI-AWLI-RGRG

[0182] SEQ ID NO:84

[0183] HZ-EGTFTSDVSSYLEGQ-AAB 14 -EFI-AWLI-RGRG

[0184] SEQ ID NO:85

[0185] HZ-EGTFTSDVSSYLEGQ-AAB 15 -EFI-AWLI-RGRG

[0186] SEQ ID NO:86

[0187] HZ-EGTFTSDVSSYLEGQ-AAB 17 -EFI-AWLI-RGRG

[0188] In the above polypeptide sequence: Z is an α-aminoisobutyric acid residue; Z1 is a 2-aminobutyric acid residue; Z2 is an isovaline residue; Z3 is a norvaline residue; Z4 is a 1-aminocyclobutanecarboxylic acid residue; Z5 is a 3-(1-naphthyl)-alanine residue; Z6 is a 3-(2-naphthyl)-alanine residue; Z7 is a 4-chlorophenylalanine residue; Z8 is a 3-chlorophenylalanine residue; Z9 is a 3-trifluoromethylphenylalanine residue; Z 10 is a 2-amino-3-methylhexanoic acid residue; B 12It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 12 -CO2H modified lysine residues; B 13 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 13 -CO2H modified lysine residues; B 14 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 14 -CO2H modified lysine residues; B 15 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 15 -CO2H modified lysine residues; B 16 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 16 -CO2H modified lysine residues; B 17 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 17 -CO2H modified lysine residues; B 18 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 18 -CO2H modified lysine residues; B 19 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 19 -CO2H modified lysine residues; B 20 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 20 -CO2H modified lysine residues.

[0189] Preferably, the salt is a salt formed by the GLP-1R polypeptide compound and one of the following compounds: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, pyrosulfuric acid, phosphoric acid, nitric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid, acetoacetic acid, pyruvic acid, trifluoroacetic acid, propionic acid, butyric acid, hexanoic acid, heptanoic acid, undecanoic acid, lauric acid, benzoic acid, salicylic acid, 2-(4-hydroxybenzoyl)benzoic acid, camphoric acid, cinnamic acid, cyclopentanepropionic acid, digluconic acid, 3-hydroxy-2- Naphthoic acid, nicotinic acid, pamoic acid, pectinic acid, persulfuric acid, 3-phenylpropionic acid, picric acid, pivalic acid, 2-hydroxyethanesulfonic acid, itaconic acid, sulfamic acid, trifluoromethanesulfonic acid, dodecylsulfuric acid, 2-naphthalenesulfonic acid, naphthalenedisulfonic acid, camphorsulfonic acid, citric acid, tartaric acid, stearic acid, lactic acid, oxalic acid, malonic acid, succinic acid, malic acid, adipic acid, alginic acid, maleic acid, fumaric acid, D-gluconic acid, mandelic acid, ascorbic acid, glucoheptanoic acid, glycerophosphoric acid, aspartic acid, sulfosalicylic acid, hemisulfuric acid or thiocyanic acid.

[0190] In another aspect, the present invention provides a pharmaceutical composition comprising the above-mentioned GLP-1R polypeptide compound and a pharmaceutically acceptable carrier.

[0191] Preferably, the pharmaceutically acceptable carrier is a pharmaceutically acceptable excipient, diluent, buffer, adjuvant, auxiliary agent or vehicle.

[0192] Preferably, the pharmaceutical composition is in the form of tablets, capsules, elixirs, syrups, lozenges, inhalants, sprays, injections, films, patches, powders, granules, blocks, emulsions, suppositories or compound preparations.

[0193] On the other hand, the present invention provides a use of the above-mentioned GLP-1R polypeptide compound or a pharmaceutically acceptable salt or a pharmaceutical composition in the preparation of a medicament for treating and / or preventing a disease or condition caused by or characterized by excessive weight, or in the preparation of a weight loss medicament.

[0194] Preferably, the disease or condition is selected from obesity, diabetes, and hyperglycemia.

[0195] Preferably the disease or condition is a human disease or condition.

[0196] Preferably, the GLP-1R polypeptide compound or its pharmaceutically acceptable salt or the pharmaceutical composition is used in the preparation of a medicament for treating and / or preventing a disease or condition caused by or characterized by excessive weight by simultaneously, separately or sequentially administering an effective amount of one or more of metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase 4 inhibitors or sodium-glucose co-transporters, or in the preparation of a weight-loss medicament.

[0197] Unless otherwise specified, the terms in this invention generally have the following meanings:

[0198] .

[0199] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages:

[0200] The present invention provides a GLP-1R polypeptide compound with a completely new structure or a pharmaceutically acceptable salt thereof, which can be prepared by artificial synthesis, i.e., a polypeptide solid phase synthesis method, has a simple structure and low cost, and is easy to promote and use as well as industrial production and application.

[0201] Compared with the existing polypeptide compound (Semaglutide), the GLP-1R polypeptide compound of the present invention has a more significant stimulatory effect on the receptor of human glucagon-like peptide-1 (GLP-1). It not only has the effects of lowering blood sugar and reducing weight, but also has a longer half-life and higher bioavailability. It can avoid the adverse reactions such as nausea and vomiting caused by long-term use of existing drugs, and can be used as an effective raw material for the preparation of drugs for treating or preventing diabetes or weight loss drugs. DETAILED DESCRIPTION

[0202] Unless otherwise defined, the technical terms used in the following examples have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. The test reagents used in the following examples, unless otherwise specified, are all conventional biochemical reagents; the experimental methods, unless otherwise specified, are all conventional methods.

[0203] The present invention is further described below in conjunction with specific embodiments.

[0204] The present invention obtains a GLP-1R polypeptide compound with a new structure by modifying the existing Semaglutide. The polypeptide compounds SEQ ID NO: 1-86 in the embodiments of the present invention can all be directly synthesized by the polypeptide solid phase method, and the polypeptides designed by the present invention are all directly synthesized by biological companies.

[0205] Example 1

[0206] Experiment on the agonist activity of peptide compounds on human GLP-1R.

[0207] HEK293 cells were co-transfected with cDNA encoding human GLP-1R, and stably transfected cell lines were selected and cultured in DMEM medium (containing 10% fetal calf serum FCS, 100 IU / mL penicillin, and 100 μg / mL streptomycin). The hypoglycemic drug Semaglutide was selected as a positive control. In the test of measuring peptide compounds, 3×10 4Cells (200 μL / well) were inoculated in 96-well plates, and peptide compounds were diluted to different multiples using culture medium and added to co-transfected HEK293 cells. After 20 minutes of cell incubation, the fluorescence readings were measured using a CisBio cAMP detection kit and a multifunctional microplate reader. A standard curve was established to convert the fluorescence readings into corresponding cAMP values. The EC values ​​of the peptides were calculated using Graphpad Prism 7.0 software using nonlinear regression. 50 The experimental results are shown in Table 1. The agonist activity of the polypeptide compound on human GLP-1R (EC 50 ,nM).

[0208] Table 1 Agonist activity of all 86 peptide compounds tested on human GLP-1R receptor (EC 50 , nM)

[0209]

[0210] Table 1 (Continued)

[0211]

[0212] Table 1 (Continued)

[0213]

[0214] As shown in Table 1, compared with the positive drug Semaglutide, all 86 peptide compounds showed more than 2 times the agonist activity on the human GLP-1R receptor (EC 50 ), which is significantly stronger than the agonist activity of semaglutide.

[0215] Example 2

[0216] Effects of peptide compounds on body weight, fat uptake, blood glucose and triglyceride levels in obese C57BL / 6J DIO mice.

[0217] C57BL / 6J mice (DIO) are particularly suitable for the study or modeling of type II diabetes models. The effects of the compounds of the present invention on weight loss, body composition and hepatic steatosis in mice were evaluated in C57BL / 6J DIO mice. In this experiment, diet-induced obese C57BL / 6J DIO male mice (23-24 weeks old) were placed in an SPF-level environment with a standard diet and free access to water. All experimental operations were carried out in accordance with the guidelines for the ethics and use of experimental animals. After 2 weeks of adaptive feeding on a standard diet, the mice were randomly assigned to treatment groups (n=10 / group) according to their body weight, and each group had a similar starting average body weight. Negative control vehicle, positive control drug Semaglutide (10nmol / kg and 30nmol / kg) and polypeptide compound (dose range 10-100nmol / kg) were dissolved in vehicle (20mM citrate buffer, pH 7.0) and injected subcutaneously to DIO mice with free feeding 30-90 minutes before the start of the dark cycle, once every three days for 15 days. The daily weight change of mice was measured throughout the study. The absolute change in body weight was calculated by subtracting the weight of the same animal before the first injection of the compound. On the 0th and 14th days, total fat mass was measured by nuclear magnetic resonance (NMR) using EchoMRI-100TM (Echo Medical Systems, Houston, TX) instrument. Blood glucose was measured using a blood glucose meter (Accu-Chek) in the tail vein blood of mice on the 15th day, and then the mice were killed to collect liver homogenate and liver triglycerides were measured on the Hitachi Modular P analyzer.

[0218] As shown in Table 2, compared with the negative control group mice, there were significant differences in the changes in body weight and fat mass of the peptide group mice ( , p<0.0001), indicating that the polypeptide compounds of the present invention (SEQ ID NO: 1-86) can effectively reduce body weight and fat mass. At the same time, compared with Semaglutide, the polypeptide group mice are more effective in reducing body weight and fat mass, and the therapeutic effect is more than 2 times. Therefore, the polypeptide compounds of the present invention are more suitable for the development of weight loss indications. In addition, from all 86 polypeptide compounds with a common motif structure, 8 representative polypeptides (including SEQ ID NO: 1, SEQ ID NO: 12, SEQ ID NO: 21, SEQ ID NO: 24, SEQ ID NO: 38, SEQ ID NO: 51, SEQ ID NO: 65, and SEQ ID NO: 77) were selected for animal treatment experiments in high, medium and low dose groups. As shown in Table 2, these 8 polypeptide compounds reduce body weight and fat mass in a dose-dependent manner. As shown in Table 3, compared with Semaglutide, the polypeptide compounds of the present invention (SEQ ID NO: 1-86) can more effectively and significantly reduce blood sugar and triglycerides, especially in reducing triglycerides. In summary, the polypeptide compound described in the present invention has more significant simultaneous blood sugar lowering and weight loss effects, and can be applied to the development of diabetes treatment drugs or weight loss drugs.

[0219] Table 2 Effects of drug administration on the body weight and fat mass of DIO mice in the experiment (n=10)

[0220]

[0221] Table 2 (Continued)

[0222]

[0223] Table 2 (Continued)

[0224]

[0225] Table 2 (Continued)

[0226]

[0227] Table 2 (Continued)

[0228]

[0229] Table 2 (Continued)

[0230]

[0231] SPSS software was used to analyze the data in this experiment, and the experimental data of each group were expressed as mean ± standard deviation (mean ± SEM). When p<0.0001, the difference between the experimental group and the control group was statistically significant.

[0232] Table 3 Effects of all 86 tested peptide compounds on blood glucose and liver triglycerides in DIO mice

[0233]

[0234] Table 3 (Continued)

[0235]

[0236] Table 3 (Continued)

[0237]

[0238] Table 3 (Continued)

[0239]

[0240] Table 3 (Continued)

[0241]

[0242] Table 3 (Continued)

[0243]

[0244] SPSS software was used to analyze the data in this experiment, and the experimental data of each group were expressed as mean ± standard deviation (mean ± SEM). When p<0.0001, the difference between the experimental group and the control group was statistically significant.

[0245] Example 3

[0246] In vivo pharmacokinetic study of the polypeptide compound of the present invention.

[0247] The pharmacokinetic properties of the polypeptide compounds of the present invention were evaluated in cynomolgus monkeys. The compound was administered intravenously or subcutaneously (0.2 mg / kg) in a single dose of 0.21 ml / kg in 20 mM citrate buffer (pH 7.0). Blood was collected from each animal at 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 204, 240 and 312 hours after administration. After solid phase extraction, the plasma concentration of the polypeptide compound was determined by LC / MS method. The in vivo half-life (T) was calculated using Phoenix software. 1 / 2 ) and bioavailability F(%).

[0248] It can be seen from the results of the above experiment Table 4 that compared with Semaglutide, the half-life of the polypeptide compounds (SEQ ID NO: 1-86) provided by the present invention in animals is more than 40 hours. Compared with Semaglutide, the polypeptide compounds (SEQ ID NO: 1-86) provided by the present invention show a longer half-life and higher bioavailability than Semaglutide, so the polypeptide compounds provided by the present invention have a better long-term therapeutic effect than Semaglutide. Therefore, the long-acting polypeptide compounds (SEQ ID NO: 1-86) of the present invention are more suitable for the development of blood sugar and weight reduction indications.

[0249] Table 4 Half-life T after single subcutaneous administration of 0.2 mg / kg to male cynomolgus monkeys 1 / 2 (hr) and bioavailability F (%)

[0250]

[0251] Table 4 (Continued)

[0252]

[0253] It can be seen from the above examples that the polypeptide compound of the present invention is a class of highly effective agonist polypeptide compounds, which have an agonist activity on human GLP-1R receptor (EC 50 ) is significantly stronger than Semaglutide, and is also significantly better than Semaglutide in terms of lowering blood sugar and reducing weight, with a longer half-life and higher bioavailability. It can be used as an effective raw material to prepare drugs for treating or preventing diabetes or weight loss drugs.

[0254] Finally, it should be noted that there are other ways to implement the present invention. Accordingly, the embodiments of the present invention are described as examples, but are not limited to the contents described in the present invention, and may also be modified within the scope of the present invention or added to the claims. All publications or patents cited in the present invention will be used as references of the present invention.

[0255] The above description is only a preferred embodiment of the present invention, which is only illustrative for the present invention and is not intended to limit the protection scope of the present invention. For those skilled in the art, the present invention may have various changes and variations. Any changes, modifications, equivalent substitutions, replacements, combinations, simplifications, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A GLP-1R polypeptide compound or a pharmaceutically acceptable salt thereof, characterized in that: The amino acid sequence of the GLP-1R polypeptide compound is selected from any one of the following: SEQ ID NO:7 H-Z-EGTFTSDVSSYLEGQ-A-A-B 16 -EFI-Z1-W-L-V-RGRG SEQ ID NO:51 H-Z-EGTFTSDVSSYLEGQ-A-A-B 15 -EFI-Z1-W-L-V-RGRG SEQ ID NO:52 H-Z-EGTFTSDVSSYLEGQ-A-A-B 17 -EFI-Z1-W-L-V-RGRG SEQ ID NO:53 H-Z-EGTFTSDVSSYLEGQ-A-A-B 18 -EFI-Z1-W-L-V-RGRG SEQ ID NO:54 H-Z-EGTFTSDVSSYLEGQ-A-A-B 14 -EFI-Z1-W-L-V-RGRG SEQ ID NO:55 H-Z-EGTFTSDVSSYLEGQ-A-A-B 19 -EFI-Z1-W-L-V-RGRG SEQ ID NO:56 H-Z-EGTFTSDVSSYLEGQ-A-A-B 20 -EFI-Z1-W-L-V-RGRG SEQ ID NO:57 H-Z-EGTFTSDVSSYLEGQ-A-A-B 13 -EFI-Z1-W-L-V-RGRG In the above polypeptide sequence: Z is an α-aminoisobutyric acid residue; Z1 is a 2-aminobutyric acid residue; B 13 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 13 -CO2H modified lysine residues; B 14 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 14 -CO2H modified lysine residues; B 15 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 15 -CO2H modified lysine residues; B 16 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 16 -CO2H modified lysine residues; B 17 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 17 -CO2H modified lysine residues; B 18 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 18 -CO2H modified lysine residues; B 19 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 19 -CO2H modified lysine residues; B 20 It is the side chain ε-amino group ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2) 20 -CO2H modified lysine residues.

2. The GLP-1R polypeptide compound or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The salt is a salt formed by the GLP-1R polypeptide compound and any one of the following compounds: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, pyrosulfuric acid, phosphoric acid, nitric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid, acetoacetic acid, pyruvic acid, trifluoroacetic acid, propionic acid, butyric acid, hexanoic acid, heptanoic acid, undecanoic acid, lauric acid, benzoic acid, salicylic acid, 2-(4-hydroxybenzoyl)benzoic acid, camphoric acid, cinnamic acid, cyclopentanepropionic acid, digluconic acid, 3-hydroxy-2-naphthalene Formic acid, nicotinic acid, pamoic acid, pectinic acid, persulfuric acid, 3-phenylpropionic acid, picric acid, pivalic acid, 2-hydroxyethanesulfonic acid, itaconic acid, sulfamic acid, trifluoromethanesulfonic acid, dodecylsulfuric acid, 2-naphthalenesulfonic acid, naphthalene disulfonic acid, camphorsulfonic acid, citric acid, tartaric acid, stearic acid, lactic acid, oxalic acid, malonic acid, succinic acid, malic acid, adipic acid, alginic acid, maleic acid, fumaric acid, D-gluconic acid, mandelic acid, ascorbic acid, glucoheptanoic acid, glycerophosphoric acid, aspartic acid, sulfosalicylic acid, hemisulfuric acid or thiocyanic acid.

3. Use of the GLP-1R polypeptide compound or a pharmaceutically acceptable salt thereof according to claim 1 in the preparation of a drug for reducing body weight or fat mass, or in the preparation of a weight loss drug.

4. A pharmaceutical composition, characterized in that It comprises the GLP-1R polypeptide compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 2 and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition according to claim 4, characterized in that The pharmaceutically acceptable carrier is a pharmaceutically acceptable excipient, diluent, buffer or adjuvant.

6. The pharmaceutical composition according to claim 4, characterized in that The dosage form of the pharmaceutical composition is tablets, capsules, elixirs, syrups, lozenges, inhalants, sprays, injections, films, patches, powders, granules, blocks, emulsions, suppositories or compound preparations.

7. Use of the pharmaceutical composition according to claim 4 in the preparation of a drug for reducing body weight or fat mass, or in the preparation of a drug for weight loss.

8. Use of the GLP-1R polypeptide compound or a pharmaceutically acceptable salt thereof according to claim 1 or the pharmaceutical composition according to claim 5 in the preparation of a medicament for treating obesity, diabetes or hyperglycemia.

9. Use of the GLP-1R polypeptide compound or a pharmaceutically acceptable salt thereof according to claim 1 or the pharmaceutical composition according to claim 5 in combination with one or more of metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase 4 inhibitors or sodium-glucose co-transporters in the preparation of a medicament for reducing body weight or fat mass, or in the preparation of a weight-loss medicament.